Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial

Bibliographic Details
Title:	Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial
Authors:	Xu, Rui-Hua, Muro, Kei, Morita, Satoshi, Iwasa, Satoru, Han, Sae Won, Wang, Wei, Kotaka, Masahito, Nakamura, Masato, Ahn, Joong Bae, Deng, Yan-Hong, Kato, Takeshi, Cho, Sang-Hee, Ba, Yi, Matsuoka, Hiroshi, Lee, Keun-Wook, Zhang, Tao, Yamada, Yasuhide, Sakamoto, Junichi, Park, Young Suk, Kim, Tae Won
Source:	In The Lancet Oncology May 2018 19(5):660-671
Database:	ScienceDirect